Short answer
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
Cullinan Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Full results and management commentary contained in Exhibit 99.1
- Investor focus: cash position, R&D spending, pipeline progress, and updated outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Cash and investments $356.0M, supporting operations into 2029 under the current plan and reducing near-term financing risk
- Net loss narrowed to $53.7M from $70.1M, with R&D expense falling to $44.4M from $61.0M
- CLN-049 potentially registrational Phase 2 AML study begins Q3 2026 following positive FDA End-of-Phase 1 feedback
- CLN-978 multi-dose data expected in RA in Q3 2026 and SLE in Q4 2026, with Phase 2 expansions planned for early 2027
- Zipalertinib PDUFA action date February 27, 2027, with Cullinan eligible for $30M and up to $100M upon U.S. approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cullinan Therapeutics, Inc. 8-K filings
Get the next CGEM 8-K as it lands
Follow CGEM for push alerts, or ask the research agent what this filing means.